Skip to main content
. 2019 Dec;7(23):776. doi: 10.21037/atm.2019.11.38

Figure 3.

Figure 3

LAG-3, CTLA-4, CD8+, recurrence-free survival (RFS), and overall survival (OS) in patients with esophageal squamous cell carcinoma (ESCC). (A) RFS by LAG-3 and CTLA-4; (B) OS by LAG-3 and CTLA-4; (C) RFS by LAG-3 and CD8+; (D) OS by LAG-3 and CD8; (E) RFS by CTLA-4 and CD8. (F) OS by CTLA-4 and CD8+. LAG-3, lymphocyte activation gene-3; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4.